Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies
Phase 2 Completed
647 enrolled 17 charts
Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer
Phase 2 Completed
37 enrolled 9 charts
BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer
Phase 2 Completed
334 enrolled 14 charts
Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma
Phase 2 Completed
60 enrolled 8 charts
MK-2206-003
Phase 1 Completed
77 enrolled 24 charts
Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery
Phase 2 Completed
18 enrolled 7 charts
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
Phase 2 Completed
16 enrolled 7 charts
MK-2206-002
Phase 1 Completed
104 enrolled 28 charts
Akt Inhibitor MK2206 in Treating Patients With Advanced Breast Cancer
Phase 2 Completed
30 enrolled 7 charts
AKT Inhibitor MK-2206 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Phase 2 Completed
19 enrolled 8 charts
A Combination Therapy Study of MK-2206 and AZD6244 in Participants With Advanced Solid Tumors (MK-2206-010)
Phase 1 Completed
63 enrolled 17 charts
MK2206 in Combination With Anastrozole, Fulvestrant, or Anastrozole and Fulvestrant in Treating Postmenopausal Women With Metastatic Breast Cancer
Phase 1 Completed
31 enrolled
Akt Inhibitor MK2206 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Phase 2 Completed
21 enrolled 11 charts
Akt Inhibitor MK2206 in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Phase 2 Completed
22 enrolled 9 charts
Akt Inhibitor MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase 1/2 Completed
15 enrolled 13 charts
MK2206 and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Metastatic Breast Cancer
Phase 1 Completed
34 enrolled
Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery
Phase 1 Completed
42 enrolled
MC1079
Phase 2 Completed
12 enrolled
MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy
Phase 2 Completed
80 enrolled 10 charts
A Phase II Study of Akt Inhibitor MK2206 in the Treatment of Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer
Phase 2 Completed
6 enrolled 7 charts
MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery
Phase 2 Completed
8 enrolled 8 charts
S1115
Phase 2 Completed
137 enrolled 12 charts
Study of MK-2206 in Patients With Metastatic Neuroendocrine Tumors (NET)
Phase 2 Completed
11 enrolled 6 charts
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
Phase 2 Completed
75 enrolled 9 charts
MK-2206 and AZD6244 in Patients With Advanced Colorectal Carcinoma
Phase 2 Completed
21 enrolled 11 charts
A Study of MK2206 in Locally Advanced or Metastatic Solid Tumors (2206-007)
Phase 1 Completed
24 enrolled
Safety and Tolerability of Different Dose Combinations of Ridaforolimus With MK-2206 or MK-0752 for Participants With Advanced Cancer (MK-8669-049)
Phase 1 Completed
65 enrolled
Akt Inhibitor MK2206 in Combination With Lapatinib Ditosylate in Patients With Advanced or Metastatic Solid Tumors or Breast Cancer
Phase 1 Completed
28 enrolled
MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia
Phase 1 Completed
45 enrolled
MK-2206, Paclitaxel and Trastuzumab in Treating Patients With HER2-overexpressing Solid Tumor Malignancies
Phase 1 Completed
17 enrolled 7 charts